Ikena Oncology Inc. has announced an amendment to its employment agreement with Dr. Jotin Marango, effective July 15, 2025. The amended agreement introduces new compensation terms that provide Dr. Marango with additional benefits in the event of termination without cause or resignation during a specified change in control period. This period began on March 18, 2025, in connection with Ikena's planned merger with Inmagene Biopharmaceutics, previously announced on December 23, 2024, and will last until the 12-month anniversary of the merger's effective time. Under these circumstances, Dr. Marango's time-based stock options and awards will be fully accelerated, becoming exercisable and nonforfeitable as of his termination date or the change in control date, whichever is later. The full text of the agreement amendment will be included in the upcoming Form 10-Q filing for the quarter ending June 30, 2025.